For US Healthcare Professionals

Sign up to get one-on-one HEMLIBRA support from your local Account and Community Manager (ACM)

Get Started
Vea esta página en español

What can you expect from your ACM?

Whether you are considering HEMLIBRA or are already on treatment, ACMs are here to help answer all your HEMLIBRA questions—everything from how HEMLIBRA works to understanding insurance coverage options. ACMs are Genentech employees and do not provide medical advice. Always talk to your doctor about treatment options.

Who is your ACM?

Your local ACM is part of your hemophilia community and is a Genentech employee. They are experts on HEMLIBRA.

Sign up below so your local ACM can reach out to you. Plus, you’ll receive a few emails with information on topics such as:

HEMLIBRA® (emicizumab-kxwh) Connect with an Account and Community Manager icon
  • HEMLIBRA information and tips
  • Real stories from people taking HEMLIBRA
  • Understanding insurance coverage and financial assistance options
  • Opportunities to connect with our team and our HEMLIBRA ambassadors

"Our ACM gave a face and name to the process of starting a new treatment. It's nice to know that you have someone to provide you with answers about HEMLIBRA."

— Julia, late 50s, mother of Louis, a person treated with HEMLIBRA

Sign Up to Connect With Your Local ACM

All fields required*

You are living with:*
Are you currently on HEMLIBRA?*
The person you care for is living with:*
Is the person you care for currently on HEMLIBRA?*

By submitting this form, I am requesting disease education and other materials from and on behalf of Genentech and its affiliates. This may include information about products and services, including co-pay assistance or other patient support, opportunities to participate in surveys or provide feedback, or other topics. I understand that my personal information, some of which may be considered sensitive information, such as information about health conditions, will be used and disclosed as described in Genentech’s Privacy Policy, and that I may be contacted using the information I have provided. I understand providing this agreement is voluntary and plays no role in getting my medicine, and that I may opt out of receiving this information at any time by calling 877-436-3683. By submitting this form, I confirm that I am 18 years of age or older and that I agree to the Terms & Conditions.

Thanks for Signing Up!

 

We’re glad to provide you with resources

Thanks for joining. Be on the lookout for helpful emails from us soon. We look forward to being a resource for you to learn more about HEMLIBRA. If you have any immediate questions, please reach out to your local Account and Community Manager.

Contact Your Local ACM

Who is your local ACM?

Please enter your ZIP Code below.

NEXT: Frequently Asked Questions

Important Safety Information & Indication

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include: 

  • Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood  vessels that may cause harm to your kidneys, brain, and other organs 
  • Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head  

Talk to your doctor about the signs and symptoms of these serious side effects, which can include: 

  • Confusion
  • Stomach, chest, or back pain
  • Weakness
  • Nausea or vomiting
  • Swelling, pain, or redness
  • Feeling sick or faint
  • Decreased urination
  • Swelling of arms and legs
  • Yellowing of skin and eyes
  • Eye pain, swelling, or trouble seeing
  • Fast heart rate
  • Numbness in your face
  • Headache
  • Shortness of breath
  • Coughing up blood

If you experience any of these symptoms during or after treatment with HEMLIBRA, get medical help right away. 

Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total. 

Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).

The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.

What else should I know about HEMLIBRA?

See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

  • Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
  • You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care. 

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Only use HEMLIBRA for the condition it was prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

Since HEMLIBRA was tested in males, there is no information on whether HEMLIBRA may impact your unborn baby or breast milk. Females who are able to become pregnant should use birth control during treatment.

Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.